Targeting the TGFß signaling in cancer progression - Enza Lonardo - IGB-CNR
Abstract:
Transforming Growth Factor-beta (TGFβ) signaling plays a critical role in the progression of pancreatic and colorectal cancer, making it an attractive target for therapeutic intervention. Aberrant activation of TGFβ signaling is implicated in the initiation, progression, and metastasis of these aggressive malignancies. TGFβ promotes tumor cell proliferation, angiogenesis, epithelial-to-mesenchymal transition (EMT), and immune evasion, facilitating tumor growth and metastatic spread. Targeted inhibition of TGFβ signaling has demonstrated promising results in preclinical studies, o ering potential to enhance the e ectiveness of conventional therapies and stimulate anti-tumor immune responses in both types of cancer. Various therapeutic approaches, such as small molecule inhibitors, monoclonal antibodies, and gene therapies, are being explored to target TGFβ signaling. Combination strategies that target multiple aspects of the TGFβ pathway, in addition to combining therapies with standard treatments, provide a comprehensive approach to address the intricate mechanisms underlying pancreatic and colorectal cancer progression.
Host: Anna Chiara De Luca (
Conference Room, CNR, P. Castellino Campus